Charlotta Liljebris
Direttore Tecnico/Scientifico/R&S presso XSPRAY PHARMA AB
Profilo
Charlotta Liljebris is currently the Deputy Director at Liljebris Consulting Ab and the Vice President-Research & Development at Xspray Pharma AB.
Previously, she worked as an Independent Director at Sprint Bioscience AB, Director at Recipharm OT Chemistry AB, Director at Connect Uppsala, Principal at Biovitrum AB, and Vice President-Development at Aprea Therapeutics AB.
Dr. Liljebris holds a graduate and doctorate degree from the University of Uppsala.
Posizioni attive di Charlotta Liljebris
Società | Posizione | Inizio |
---|---|---|
XSPRAY PHARMA AB | Direttore Tecnico/Scientifico/R&S | 01/01/2018 |
Liljebris Consulting Ab | Corporate Officer/Principal | - |
Precedenti posizioni note di Charlotta Liljebris
Società | Posizione | Fine |
---|---|---|
Connect Uppsala | Direttore/Membro del Consiglio | - |
Recipharm OT Chemistry AB
Recipharm OT Chemistry AB Pharmaceuticals: MajorHealth Technology Part of Recipharm AB, Recipharm OT Chemistry AB develops and manufactures drug dosage forms and inhalation products & devices. The company is based in Uppsala, Sweden. | Direttore/Membro del Consiglio | - |
Biovitrum AB
Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Corporate Officer/Principal | - |
SPRINT BIOSCIENCE AB | Direttore/Membro del Consiglio | - |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Corporate Officer/Principal | - |
Formazione di Charlotta Liljebris
University of Uppsala | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
XSPRAY PHARMA AB | Health Technology |
SPRINT BIOSCIENCE AB | Health Technology |
Aziende private | 5 |
---|---|
Biovitrum AB
Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Commercial Services |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Health Technology |
Recipharm OT Chemistry AB
Recipharm OT Chemistry AB Pharmaceuticals: MajorHealth Technology Part of Recipharm AB, Recipharm OT Chemistry AB develops and manufactures drug dosage forms and inhalation products & devices. The company is based in Uppsala, Sweden. | Health Technology |
Liljebris Consulting Ab | |
Connect Uppsala |
- Borsa valori
- Insiders
- Charlotta Liljebris